Get regular updates to your inbox.
People with sarcoidosis in three of the hardest hit English-speaking cities during the initial stages of the COVID-19 pandemic — London, New Orleans, and New York — reported considerable disruptions in healthcare, a survey study has found. Patients also had concerns for their own survival and believed that they were…
The Foundation for Sarcoidosis Research (FSR) is searching for volunteers to join its advocacy program, designed to support the sarcoidosis community in a number of ways, from raising awareness to coaching other advocates to providing one-on-one support to patients and caregivers. The program consists of three advocate roles:…
aTyr Pharma has announced that its investigational immunomodulatory therapy for pulmonary sarcoidosis will now be called efzofitimod instead of ATYR1923. The change comes after the United States Adopted Names (USAN) Council and the World Health Organization’s (WHO) International Nonproprietary Name (INN) expert committee selected efzofitimod as the generic name…
A short, in-hospital exercise program was found to decrease the levels of fats, or lipids, in the blood of people with sarcoidosis and to improve their physical health. In fact, researchers said that changes in the lipid profile could potentially be used to determine how well a patient is…
An association has been found between active sarcoidosis, inflammation, and the presence of low levels of white blood cells, called lymphocytes, that are involved in immune defense. This finding, by researchers at the University of Illinois Chicago (UIC), could be the first step toward the development of a new biomarker…
Get regular updates to your inbox.